These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25338742)

  • 21. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting.
    Geddie ML; Kohli N; Kirpotin DB; Razlog M; Jiao Y; Kornaga T; Rennard R; Xu L; Schoerberl B; Marks JD; Drummond DC; Lugovskoy AA
    MAbs; 2017 Jan; 9(1):58-67. PubMed ID: 27854147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy.
    Gupta S; Jiskoot W; Schöneich C; Rathore AS
    J Pharm Sci; 2022 Apr; 111(4):903-918. PubMed ID: 34890632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
    Corti A; Gasparri AM; Sacchi A; Colombo B; Monieri M; Rrapaj E; Ferreri AJM; Curnis F
    Mol Pharm; 2020 Oct; 17(10):3813-3824. PubMed ID: 32805112
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating peptide half-life in serum from tunable, sequence-related physicochemical properties.
    Cavaco M; Valle J; Flores I; Andreu D; A R B Castanho M
    Clin Transl Sci; 2021 Jul; 14(4):1349-1358. PubMed ID: 33641212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
    Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
    MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals.
    Jenkins N; Murphy L; Tyther R
    Mol Biotechnol; 2008 Jun; 39(2):113-8. PubMed ID: 18327554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Machine Learning Enables Accurate Prediction of Asparagine Deamidation Probability and Rate.
    Delmar JA; Wang J; Choi SW; Martins JA; Mikhail JP
    Mol Ther Methods Clin Dev; 2019 Dec; 15():264-274. PubMed ID: 31890727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications.
    Wang S; Zhang W; Yang B; Zhang X; Fang J; Rui H; Chen Z; Gu J; Chen Z; Xu J
    Antib Ther; 2024 Jul; 7(3):189-198. PubMed ID: 39036070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of a 2,2'-Azobis (2-Amidinopropane) Dihydrochloride Stress Model as an Indicator of Oxidation Susceptibility for Monoclonal Antibodies.
    Dion MZ; Wang YJ; Bregante D; Chan W; Andersen N; Hilderbrand A; Leiske D; Salisbury CM
    J Pharm Sci; 2018 Feb; 107(2):550-558. PubMed ID: 28989015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Engineering of Conus Peptides as Therapeutic Leads.
    Daniel JT; Clark RJ
    Adv Exp Med Biol; 2017; 1030():229-254. PubMed ID: 29081056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy.
    Lobo SA; Bączyk P; Wyss B; Widmer JC; Jesus LP; Gomes J; Batista AP; Hartmann S; Wassmann P
    J Pharm Biomed Anal; 2021 Jan; 192():113650. PubMed ID: 33065403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
    Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
    MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyphenation of strong cation exchange chromatography to native mass spectrometry for high throughput online characterization of charge heterogeneity of therapeutic monoclonal antibodies.
    Ma F; Raoufi F; Bailly MA; Fayadat-Dilman L; Tomazela D
    MAbs; 2020; 12(1):1763762. PubMed ID: 32370592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational optimization of a monoclonal antibody for simultaneous improvements in its solution properties and biological activity.
    Kumar S; Roffi K; Tomar DS; Cirelli D; Luksha N; Meyer D; Mitchell J; Allen MJ; Li L
    Protein Eng Des Sel; 2018 Jul; 31(7-8):313-325. PubMed ID: 30189027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering bioactive peptide-based therapeutic molecules.
    Ryu JS; Cho AY; Seo SW; Min H
    Methods Mol Biol; 2014; 1088():35-50. PubMed ID: 24146395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improvement of Biophysical Properties and Affinity of a Human Anti-L1CAM Therapeutic Antibody through Antibody Engineering Based on Computational Methods.
    Chae H; Cho S; Jeong M; Kwon K; Choi D; Lee J; Nam W; Hong J; Lee J; Yoon S; Hong H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Holistic in silico developability assessment of novel classes of small proteins using publicly available sequence-based predictors.
    Pais DAM; Mayer JA; Felderer K; Batalha MB; Eichner T; Santos ST; Kumar R; Silva SD; Kaufmann H
    J Comput Aided Mol Des; 2024 Aug; 38(1):30. PubMed ID: 39164492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
    Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
    Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering an anti-CD52 antibody for enhanced deamidation stability.
    Qiu H; Wei R; Jaworski J; Boudanova E; Hughes H; VanPatten S; Lund A; Day J; Zhou Y; McSherry T; Pan CQ; Sendak R
    MAbs; 2019 Oct; 11(7):1266-1275. PubMed ID: 31199181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies.
    Dashivets T; Stracke J; Dengl S; Knaupp A; Pollmann J; Buchner J; Schlothauer T
    MAbs; 2016; 8(8):1525-1535. PubMed ID: 27612038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.